ReviewEuropean respiratory review : an official journal of the European Respiratory Society2020
Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06635863 (Immunosuppression Versus Medical Therapy for UN-explained Low Ejection Fraction and VT), which is not on this map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunosuppression Versus Medical Therapy for UN-explained Low Ejection Fraction and VT
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026Guideline
- Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.The European respiratory journal · 2026Trial
- Trial
- Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective 'target trial' emulated with Swedish real-world data.Respirology (Carlton, Vic.) · 2021Trial
- Sarcoidosis: A Clinical Trials Perspective.Pulmonary therapy · 2026Review
- Treatable traits approach for personalised management of sarcoidosis.BMJ open respiratory research · 2026Review
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Legumain Restrains Granuloma Formation by Inhibiting mTORC1/STAT1-Mediated M1 Macrophage Polarization in Sarcoidosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- From guidelines to reality: how do physicians really manage sarcoidosis?BMC pulmonary medicine · 2026Article
- Symptomatic Sarcoidosis Treated with ActharPulmonary therapy · 2026Article
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Pulmonary sarcoidosis with pleural involvement in a 44-year-old patient: a case report.Frontiers in medicine · 2026Article
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
- Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- Isolated splenic sarcoidosis: A case report.Anales del sistema sanitario de Navarra · 2025Article
- Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Sarcoidosis.Tuberculosis and respiratory diseases · 2025Article
- Disparate Prednisone Starting Dosages for Systemic Corticosteroid-Naïve Veterans With Active Sarcoidosis.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.Neurology. Clinical practice · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 20 institutions in 7 countries.
Funding
Abstract
Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations.The modified Delphi process used three rounds. The first round focused on qualitative data collection with open-ended questions to ensure comprehensive inclusion of expert concepts. Rounds 2 and 3 applied quantitative assessments using an 11-point Likert scale to identify consensus.Key consensus points included glucocorticoids as initial therapy for most patients, with non-biologics (immunomodulators), usually methotrexate, considered in severe or extrapulmonary disease requiring prolonged treatment, or as a steroid-sparing intervention in cases with high risk of steroid toxicity. Biologic therapies might be considered as additive therapy if non-biologics are insufficiently effective or are not tolerated with initial biologic therapy, usually with a tumour necrosis factor-α inhibitor, typically infliximab.The Delphi methodology provided a platform to gain potentially valuable insight and interim guidance while awaiting evidenced-based contributions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.